Biotech

Horizon Pharma to Present at the Piper Jaffray 25th Annual Healthcare Conference

DEERFIELD, IL: ...

Expert Panel to Discuss Prima BioMed's CVac Clinical Trial Data in Ovarian Cancer

SYDNEY, AUSTRALIA: ...

Threshold Pharmaceuticals Announces New Clinical Data on TH-302 and Avastin(R) (Bevacizumab) in Recurrent Glioblastoma Following Bevacizumab Failure

SOUTH SAN FRANCISCO, CA: Data to Be Presented at the 2013 WFNO/SNO Meeting ...

European Medicines Agency Accepts Marketing Authorization Application for The Medicines Company's Fibrocaps Hemostatic Agent

PARSIPPANY, NJ: ...

Brain Tumor Cell Targeting Technology: Data to Be Presented at the Society of Neuro-Oncology Quadrennial Meeting

TORONTO, ONTARIO: ...

Omni Bio Announces Reduction in Inflammatory Myocardial Injury With Its Lead Recombinant Molecule

DENVER, CO: Fc-AAT Shown to Be Effective in Mouse Model of Myocardial Ischemia ...

RepliCel Reports Third Quarter 2013 Financial Results and Provides Corporate Update

VANCOUVER, BRITISH COLUMBIA: ...

Prima BioMed's CEO to Present at 11th Annual Commercial Translation of Regenerative Medicine Meeting

SYDNEY, AUSTRALIA: ...

Q Therapeutics Receives Orphan Drug Designation From U.S. Food & Drug Administration for Q-Cells(R) for Treatment of ALS

SALT LAKE CITY, UT: ...

ProMetic Receives $5.1 Million Purchase Order from Multinational Client

LAVAL, QUEBEC: - First purchase order relating to July 8, 2013 secured licensing and long term resin supply agreement - Purchase order confirms forecasted annual revenues arising from related custom resin developmen ...